Differences in cancer prevalence among CHEK2 carriers identified via multi-gene panel testing
Purpose: Although CHEK2 is a well-established cancer gene, questions remain including whether risks vary substantially between different variants and whether biallelic carriers have higher risks than heterozygotes. We report on a cohort of individuals with CHEK2 pathogenic and likely pathogenic variants (collectively, PV) in order to better characterize this gene.
Methods: We retrospectively queried samples submitted for multi-gene hereditary cancer testing to identify individuals with CHEK2 PVs and assessed differences in phenotypes among various genotypes.
Results: CHEK2 PVs were identified in 2508 individuals, including 32 individuals with biallelic CHEK2 PVs. Breast (female, 59.9% and male, 11.8%), prostate (20.1%), and colorectal (3.5%), were among the most frequently reported cancers. Select missense PVs showed similar cancer prevalence to truncating PVs while some others showed lower prevalence. No significant differences were observed between biallelic carriers and heterozygotes.
Conclusions: Our data support that some, but not all, CHEK2 missense PVs demonstrate lower cancer prevalence; further studies are needed to continue characterizing possible variant specific risks. In addition, biallelic CHEK2 PVs do not appear to be associated with a more severe phenotype than single CHEK2 PVs. Furthermore, co-occurrences with PVs in other cancer risk genes are common among CHEK2 heterozygotes and often warrant additional management.
PSMB8 Antibody |
|||
| E94054 | EnoGene | 100μg | EUR 255 |
|
Description: Available in various conjugation types. |
|||
PSMB8 Antibody |
|||
| E97340 | EnoGene | 100ul | EUR 255 |
|
Description: Available in various conjugation types. |
|||
PSMB8 Antibody |
|||
| E314816 | EnoGene | 100ug/200ul | EUR 295 |
|
Description: Available in various conjugation types. |
|||
PSMB8 antibody |
|||
| 70R-13550 | Fitzgerald | 100 ul | EUR 550 |
|
Description: Affinity purified Rabbit polyclonal PSMB8 antibody |
|||
PSMB8 antibody |
|||
| 70R-19589 | Fitzgerald | 50 ul | EUR 289 |
|
Description: Rabbit polyclonal PSMB8 antibody |
|||
PSMB8 Antibody |
|||
| 1-CSB-PA116429 | Cusabio |
|
|
|
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;ELISA:1:1000-1:2000, WB:1:200-1:1000, IHC:1:25-1:100 |
|||
PSMB8 antibody |
|||
| BF0434 | Nova Lifetech | 100ug | EUR 355 |
PSMB8 Antibody |
|||
| MBS7113266-005mL | MyBiosource | 0.05mL | EUR 190 |
PSMB8 Antibody |
|||
| MBS7113266-01mL | MyBiosource | 0.1mL | EUR 270 |
PSMB8 Antibody |
|||
| MBS7113266-5x01mL | MyBiosource | 5x0.1mL | EUR 1205 |
PSMB8 Antibody |
|||
| MBS7129229-005mL | MyBiosource | 0.05mL | EUR 190 |
PSMB8 Antibody |
|||
| MBS7129229-01mL | MyBiosource | 0.1mL | EUR 270 |
PSMB8 Antibody |
|||
| MBS7129229-5x01mL | MyBiosource | 5x0.1mL | EUR 1205 |
PSMB8 Antibody |
|||
| MBS7129230-005mL | MyBiosource | 0.05mL | EUR 190 |
PSMB8 Antibody |
|||
| MBS7129230-01mL | MyBiosource | 0.1mL | EUR 270 |
PSMB8 Antibody |
|||
| MBS7129230-5x01mL | MyBiosource | 5x0.1mL | EUR 1205 |
PSMB8 antibody |
|||
| MBS9405580-01mL | MyBiosource | 0.1mL | EUR 420 |
PSMB8 antibody |
|||
| MBS9405580-5x01mL | MyBiosource | 5x0.1mL | EUR 1740 |
PSMB8 Antibody |
|||
| MBS8500013-01mg | MyBiosource | 0.1mg | EUR 325 |
PSMB8 Antibody |
|||
| MBS8500013-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
PSMB8 Antibody |
|||
| MBS8500013-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
PSMB8 Antibody |
|||
| MBS8500013-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
PSMB8 Antibody |
|||
| MBS8500013-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
PSMB8 Antibody |
|||
| MBS5312424-01mL | MyBiosource | 0.1mL | EUR 1070 |
PSMB8 Antibody |
|||
| MBS5312424-5x01mL | MyBiosource | 5x0.1mL | EUR 4655 |
PSMB8 Antibody |
|||
| MBS9416351-01mL | MyBiosource | 0.1mL | EUR 305 |
PSMB8 Antibody |
|||
| MBS9416351-5x01mL | MyBiosource | 5x0.1mL | EUR 1230 |
PSMB8 Antibody |
|||
| BF0434-100ul | Affinity Biosciences | 100ul | EUR 210 |
|
Description: WB,IHC,IF/ICC,ELISA |
|||
PSMB8 Antibody |
|||
| BF0434-200ul | Affinity Biosciences | 200ul | Ask for price |
|
Description: WB,IHC,IF/ICC,ELISA |
|||
PSMB8 Antibody |
|||
| BF0434-50ul | Affinity Biosciences | 50ul | EUR 150 |
|
Description: WB,IHC,IF/ICC,ELISA |
|||
PSMB8 Conjugated Antibody |
|||
| C43134 | SAB | 100ul | EUR 476.4 |
PSMB8 Polyclonal Antibody |
|||
| E-AB-92394-120uL | Elabscience Biotech | 120uL | EUR 320 |
|
Description: Unconjugated |
|||
PSMB8 Polyclonal Antibody |
|||
| E-AB-92394-200uL | Elabscience Biotech | 200uL | EUR 530 |
|
Description: Unconjugated |
|||
PSMB8 Polyclonal Antibody |
|||
| E-AB-92394-60uL | Elabscience Biotech | 60uL | EUR 200 |
|
Description: Unconjugated |
|||
PSMB8 Polyclonal Antibody |
|||
| E-AB-92394-each | Elabscience Biotech | each | Ask for price |
|
Description: Unconjugated |
|||
PSMB8 Polyclonal Antibody |
|||
| A73468 | EpiGentek | 50 μl | EUR 557 |
PSMB8 Polyclonal Antibody |
|||
| E-AB-61655-120uL | Elabscience Biotech | 120uL | EUR 320 |
|
Description: Unconjugated |
|||
PSMB8 Polyclonal Antibody |
|||
| E-AB-61655-200uL | Elabscience Biotech | 200uL | EUR 530 |
|
Description: Unconjugated |
|||
PSMB8 Polyclonal Antibody |
|||
| E-AB-61655-60uL | Elabscience Biotech | 60uL | EUR 200 |
|
Description: Unconjugated |
|||
PSMB8 Polyclonal Antibody |
|||
| E-AB-61655-each | Elabscience Biotech | each | Ask for price |
|
Description: Unconjugated |
|||
PSMB8 Polyclonal Antibody |
|||
| MBS2538339-006mL | MyBiosource | 0.06mL | EUR 190 |
PSMB8 Polyclonal Antibody |
|||
| MBS2538339-012mL | MyBiosource | 0.12mL | EUR 265 |
PSMB8 Polyclonal Antibody |
|||
| MBS2538339-02mL | MyBiosource | 0.2mL | EUR 415 |
PSMB8 Polyclonal Antibody |
|||
| MBS2538339-5x02mL | MyBiosource | 5x0.2mL | EUR 1835 |
PSMB8 Polyclonal Antibody |
|||
| MBS2527805-002mL | MyBiosource | 0.02mL | EUR 140 |
PSMB8 Polyclonal Antibody |
|||
| MBS2527805-006mL | MyBiosource | 0.06mL | EUR 180 |
PSMB8 Polyclonal Antibody |
|||
| MBS2527805-012mL | MyBiosource | 0.12mL | EUR 260 |
PSMB8 Polyclonal Antibody |
|||
| MBS2527805-02mL | MyBiosource | 0.2mL | EUR 405 |
PSMB8 Polyclonal Antibody |
|||
| MBS2527805-5x02mL | MyBiosource | 5x0.2mL | EUR 1725 |
PSMB8 Polyclonal Antibody |
|||
| MBS2528965-002mL | MyBiosource | 0.02mL | EUR 140 |
PSMB8 Polyclonal Antibody |
|||
| MBS2528965-006mL | MyBiosource | 0.06mL | EUR 180 |
PSMB8 Polyclonal Antibody |
|||
| MBS2528965-012mL | MyBiosource | 0.12mL | EUR 260 |
PSMB8 Polyclonal Antibody |
|||
| MBS2528965-02mL | MyBiosource | 0.2mL | EUR 405 |
PSMB8 Polyclonal Antibody |
|||
| MBS2528965-5x02mL | MyBiosource | 5x0.2mL | EUR 1725 |
PSMB8 Conjugated Antibody |
|||
| MBS9451453-01mLAF350 | MyBiosource | 0.1mL(AF350) | EUR 480 |
PSMB8 Conjugated Antibody |
|||
| MBS9451453-01mLAF405 | MyBiosource | 0.1mL(AF405) | EUR 480 |
PSMB8 Conjugated Antibody |
|||
| MBS9451453-01mLAF488 | MyBiosource | 0.1mL(AF488) | EUR 480 |
PSMB8 Conjugated Antibody |
|||
| MBS9451453-01mLAF555 | MyBiosource | 0.1mL(AF555) | EUR 480 |
PSMB8 Conjugated Antibody |
|||
| MBS9451453-01mLBiotin | MyBiosource | 0.1mL(Biotin) | EUR 480 |
PSMB8 Polyclonal Antibody |
|||
| RD84433A-120uL | Reddot Biotech | 120μL | EUR 360 |
|
Description: The proteasome is a multicatalytic proteinase complex with a highly ordered ring-shaped 20S core structure. The core structure is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. This gene encodes a member of the proteasome B-type family, also known as the T1B family, that is a 20S core beta subunit. This gene is located in the class II region of the MHC (major histocompatibility complex). Expression of this gene is induced by gamma interferon and this gene product replaces catalytic subunit 3 (proteasome beta 5 subunit) in the immunoproteasome. Proteolytic processing is required to generate a mature subunit. Two alternative transcripts encoding two isoforms have been identified; both isoforms are processed to yield the same mature subunit. |
|||
PSMB8 Polyclonal Antibody |
|||
| RD84433A-200uL | Reddot Biotech | 200μL | EUR 630 |
|
Description: The proteasome is a multicatalytic proteinase complex with a highly ordered ring-shaped 20S core structure. The core structure is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. This gene encodes a member of the proteasome B-type family, also known as the T1B family, that is a 20S core beta subunit. This gene is located in the class II region of the MHC (major histocompatibility complex). Expression of this gene is induced by gamma interferon and this gene product replaces catalytic subunit 3 (proteasome beta 5 subunit) in the immunoproteasome. Proteolytic processing is required to generate a mature subunit. Two alternative transcripts encoding two isoforms have been identified; both isoforms are processed to yield the same mature subunit. |
|||
PSMB8 Polyclonal Antibody |
|||
| RD84433A-60uL | Reddot Biotech | 60μL | EUR 204 |
|
Description: The proteasome is a multicatalytic proteinase complex with a highly ordered ring-shaped 20S core structure. The core structure is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. This gene encodes a member of the proteasome B-type family, also known as the T1B family, that is a 20S core beta subunit. This gene is located in the class II region of the MHC (major histocompatibility complex). Expression of this gene is induced by gamma interferon and this gene product replaces catalytic subunit 3 (proteasome beta 5 subunit) in the immunoproteasome. Proteolytic processing is required to generate a mature subunit. Two alternative transcripts encoding two isoforms have been identified; both isoforms are processed to yield the same mature subunit. |
|||
PSMB8 Antibody (N-term) |
|||
| MBS9213569-008mL | MyBiosource | 0.08mL | EUR 210 |
PSMB8 Antibody (N-term) |
|||
| MBS9213569-04mL | MyBiosource | 0.4mL | EUR 430 |
PSMB8 Antibody (N-term) |
|||
| MBS9213569-5x04mL | MyBiosource | 5x0.4mL | EUR 1910 |
PSMB8 Antibody, HRP conjugated |
|||
| 1-CSB-PA018886LB01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA |
|||
PSMB8 Antibody, HRP Conjugated |
|||
| MBS7113267-005mL | MyBiosource | 0.05mL | EUR 190 |
PSMB8 Antibody, HRP Conjugated |
|||
| MBS7113267-01mL | MyBiosource | 0.1mL | EUR 270 |
PSMB8 Antibody, HRP Conjugated |
|||
| MBS7113267-5x01mL | MyBiosource | 5x0.1mL | EUR 1205 |
PSMB8 Antibody, FITC conjugated |
|||
| 1-CSB-PA018886LC01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA |
|||
OACD05288-1ML - PSMB8 Antibody |
|||
| OACD05288-1ML | Aviva Systems Biology | 1ml | EUR 649 |
OACD05289-1ML - PSMB8 Antibody |
|||
| OACD05289-1ML | Aviva Systems Biology | 1ml | EUR 659 |
OACD05290-1ML - PSMB8 Antibody |
|||
| OACD05290-1ML | Aviva Systems Biology | 1ml | EUR 639 |
PSMB8 Antibody, FITC Conjugated |
|||
| MBS7113268-005mL | MyBiosource | 0.05mL | EUR 190 |
PSMB8 Antibody, FITC Conjugated |
|||
| MBS7113268-01mL | MyBiosource | 0.1mL | EUR 270 |
PSMB8 Antibody, FITC Conjugated |
|||
| MBS7113268-5x01mL | MyBiosource | 5x0.1mL | EUR 1205 |
OAAN02231-50UL - PSMB8 Antibody |
|||
| OAAN02231-50UL | Aviva Systems Biology | 50ul | EUR 149 |
PSMB8 Antibody, Biotin conjugated |
|||
| 1-CSB-PA018886LD01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA |
|||
OACD05288-100UL - PSMB8 Antibody |
|||
| OACD05288-100UL | Aviva Systems Biology | 100ul | EUR 199 |
OACD05289-100UL - PSMB8 Antibody |
|||
| OACD05289-100UL | Aviva Systems Biology | 100ul | EUR 189 |
OACD05290-100UL - PSMB8 Antibody |
|||
| OACD05290-100UL | Aviva Systems Biology | 100ul | EUR 189 |
OAAN02231-100UL - PSMB8 Antibody |
|||
| OAAN02231-100UL | Aviva Systems Biology | 100ul | EUR 249 |
OAAN02231-200UL - PSMB8 Antibody |
|||
| OAAN02231-200UL | Aviva Systems Biology | 200ul | EUR 389 |
OAEB02189-100UG - PSMB8 Antibody |
|||
| OAEB02189-100UG | Aviva Systems Biology | 100ug | EUR 349 |
OAGA01026-100UL - PSMB8 antibody |
|||
| OAGA01026-100UL | Aviva Systems Biology | 100ul | EUR 369 |
Integration of genetic counsellors in genomic testing triage: Outcomes of a Genomic Consultation Service in British Columbia, Canada
Purpose: Clinical diagnostic genome-wide (exome or genome) sequencing (GWS) in British Columbia requires funding approval by a provincial agency on a case-by-case basis. The CAUSES Clinic was a pediatric translational trio-based GWS study at BC Children’s and Women’s Hospitals.
Referrals to the CAUSES Clinic were made through a Genomic Consultation Service (GCS), a multidisciplinary team led by genetic counsellors that provided advice regarding genomic testing for physicians considering GWS for their patients.
Here we review the outcomes of the GCS, focusing on patients not recommended for the CAUSES Study.
Methods: Demographic, clinical, and testing data were abstracted from patient charts. Logistic regression analysis was used to explore associations between demographic and clinical variables and two outcomes: the type of recommendation and referring physicians’ decisions to follow the recommendation.
Results: Of 972 GCS referrals, 248 patients were not referred to the CAUSES Study. GWS (vs. a targeted test; e.g. multi-gene panel) was more likely to be recommended to physicians of patients with ID than physicians of patients without ID (OR = 2.98; 95% CI = 1.46 to 6.27; n = 149). In total, 40% of physicians who were recommended to pursue clinical genomic testing submitted an application for funding approval; 71% of applications were approved for funding. Among approved tests, 50% resulted in a diagnosis, including 33% of targeted tests and 82% of GWS tests (χ2 (1) = 5.0, p = 0.026).
Conclusion: The GCS provided an effective model in which physicians can interface with genetic specialists, including genetic counsellors, to facilitate appropriate genomic test selection.
From Probands to Relatives: Communication of Genetic Risk for Hereditary Breast-Ovarian Cancer and Its Influence on Subsequent Testing
Background: The genetic risk communication from proband to relatives varies from family to family, and patients often need support with the communication of genetic test results and making decisions to manage hereditary cancer risks.
Objective: The aim of this study was to characterize the communication of BRCA1 or BRCA2 (BRCA1/2) genetic risk from proband to first-degree relatives (FDRs) using a social network framework.
Methods: We characterized network and nonnetwork factors to explore their association with which FDRs were told about the genetic risk and whether or not relatives underwent genetic testing. Ninety-two female probands with hereditary breast and ovarian cancer who have confirmed BRCA1/2 mutations participated in the study. Communication of hereditary breast and ovarian cancer risk was assessed between 92 probands and their 417 FDRs.
Results: Of 92 probands, 94.5% (n = 87) communicated their genetic test result to at least one of their FDRs. Of FDRs older than 18 years, 19.9% (n = 72) have genetic testing. Emotional closeness, educational level of the proband, and relative’s age were significantly associated with communicating test results with FDRs.
Conclusion: Communication of genetic risk with the FDRs after having a BRCA1/2 gene-mutation-positive test result was high in this group of cancer patients. However, the rate of genetic testing among FDRs was low.
Implications for practice: Probands’ educational level and age of relatives for cascade genetic screening should be considered during counseling. Interventions to support women with BRCA1/2 mutations during the communication process and their family members’ engagement in testing and risk-reducing strategies are needed.
PSMB8 Antibody |
|||
| E314816 | EnoGene | 100ug/200ul | EUR 295 |
|
Description: Available in various conjugation types. |
|||
PSMB8 antibody |
|||
| 70R-13550 | Fitzgerald | 100 ul | EUR 550 |
|
Description: Affinity purified Rabbit polyclonal PSMB8 antibody |
|||
PSMB8 antibody |
|||
| 70R-19589 | Fitzgerald | 50 ul | EUR 289 |
|
Description: Rabbit polyclonal PSMB8 antibody |
|||
PSMB8 Antibody |
|||
| 1-CSB-PA116429 | Cusabio |
|
|
|
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;ELISA:1:1000-1:2000, WB:1:200-1:1000, IHC:1:25-1:100 |
|||
PSMB8 antibody |
|||
| BF0434 | Nova Lifetech | 100ug | EUR 355 |
PSMB8 Antibody |
|||
| MBS7113266-005mL | MyBiosource | 0.05mL | EUR 190 |
PSMB8 Antibody |
|||
| MBS7113266-01mL | MyBiosource | 0.1mL | EUR 270 |
PSMB8 Antibody |
|||
| MBS7113266-5x01mL | MyBiosource | 5x0.1mL | EUR 1205 |
PSMB8 Antibody |
|||
| MBS7129229-005mL | MyBiosource | 0.05mL | EUR 190 |
PSMB8 Antibody |
|||
| MBS7129229-01mL | MyBiosource | 0.1mL | EUR 270 |
PSMB8 Antibody |
|||
| MBS7129229-5x01mL | MyBiosource | 5x0.1mL | EUR 1205 |
PSMB8 Antibody |
|||
| MBS7129230-005mL | MyBiosource | 0.05mL | EUR 190 |
PSMB8 Antibody |
|||
| MBS7129230-01mL | MyBiosource | 0.1mL | EUR 270 |
PSMB8 Antibody |
|||
| MBS7129230-5x01mL | MyBiosource | 5x0.1mL | EUR 1205 |
PSMB8 antibody |
|||
| MBS9405580-01mL | MyBiosource | 0.1mL | EUR 420 |
PSMB8 antibody |
|||
| MBS9405580-5x01mL | MyBiosource | 5x0.1mL | EUR 1740 |
PSMB8 Antibody |
|||
| MBS8500013-01mg | MyBiosource | 0.1mg | EUR 325 |
PSMB8 Antibody |
|||
| MBS8500013-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
PSMB8 Antibody |
|||
| MBS8500013-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
PSMB8 Antibody |
|||
| MBS8500013-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
PSMB8 Antibody |
|||
| MBS8500013-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
PSMB8 Antibody |
|||
| MBS5312424-01mL | MyBiosource | 0.1mL | EUR 1070 |
PSMB8 Antibody |
|||
| MBS5312424-5x01mL | MyBiosource | 5x0.1mL | EUR 4655 |
PSMB8 Antibody |
|||
| MBS9416351-01mL | MyBiosource | 0.1mL | EUR 305 |
PSMB8 Antibody |
|||
| MBS9416351-5x01mL | MyBiosource | 5x0.1mL | EUR 1230 |
PSMB8 Antibody |
|||
| BF0434-100ul | Affinity Biosciences | 100ul | EUR 210 |
|
Description: WB,IHC,IF/ICC,ELISA |
|||
PSMB8 Antibody |
|||
| BF0434-200ul | Affinity Biosciences | 200ul | Ask for price |
|
Description: WB,IHC,IF/ICC,ELISA |
|||
PSMB8 Antibody |
|||
| BF0434-50ul | Affinity Biosciences | 50ul | EUR 150 |
|
Description: WB,IHC,IF/ICC,ELISA |
|||
PSMB8 Conjugated Antibody |
|||
| C43134 | SAB | 100ul | EUR 476.4 |
PSMB8 Polyclonal Antibody |
|||
| E-AB-92394-120uL | Elabscience Biotech | 120uL | EUR 320 |
|
Description: Unconjugated |
|||
PSMB8 Polyclonal Antibody |
|||
| E-AB-92394-200uL | Elabscience Biotech | 200uL | EUR 530 |
|
Description: Unconjugated |
|||
PSMB8 Polyclonal Antibody |
|||
| E-AB-92394-60uL | Elabscience Biotech | 60uL | EUR 200 |
|
Description: Unconjugated |
|||
PSMB8 Polyclonal Antibody |
|||
| E-AB-92394-each | Elabscience Biotech | each | Ask for price |
|
Description: Unconjugated |
|||
PSMB8 Polyclonal Antibody |
|||
| A73468 | EpiGentek | 50 μl | EUR 557 |
PSMB8 Polyclonal Antibody |
|||
| E-AB-61655-120uL | Elabscience Biotech | 120uL | EUR 320 |
|
Description: Unconjugated |
|||
PSMB8 Polyclonal Antibody |
|||
| E-AB-61655-200uL | Elabscience Biotech | 200uL | EUR 530 |
|
Description: Unconjugated |
|||
PSMB8 Polyclonal Antibody |
|||
| E-AB-61655-60uL | Elabscience Biotech | 60uL | EUR 200 |
|
Description: Unconjugated |
|||
PSMB8 Polyclonal Antibody |
|||
| E-AB-61655-each | Elabscience Biotech | each | Ask for price |
|
Description: Unconjugated |
|||
PSMB8 Polyclonal Antibody |
|||
| MBS2538339-006mL | MyBiosource | 0.06mL | EUR 190 |
PSMB8 Polyclonal Antibody |
|||
| MBS2538339-012mL | MyBiosource | 0.12mL | EUR 265 |
PSMB8 Polyclonal Antibody |
|||
| MBS2538339-02mL | MyBiosource | 0.2mL | EUR 415 |
PSMB8 Polyclonal Antibody |
|||
| MBS2538339-5x02mL | MyBiosource | 5x0.2mL | EUR 1835 |
PSMB8 Polyclonal Antibody |
|||
| MBS2527805-002mL | MyBiosource | 0.02mL | EUR 140 |
PSMB8 Polyclonal Antibody |
|||
| MBS2527805-006mL | MyBiosource | 0.06mL | EUR 180 |
PSMB8 Polyclonal Antibody |
|||
| MBS2527805-012mL | MyBiosource | 0.12mL | EUR 260 |
PSMB8 Polyclonal Antibody |
|||
| MBS2527805-02mL | MyBiosource | 0.2mL | EUR 405 |
PSMB8 Polyclonal Antibody |
|||
| MBS2527805-5x02mL | MyBiosource | 5x0.2mL | EUR 1725 |
PSMB8 Polyclonal Antibody |
|||
| MBS2528965-002mL | MyBiosource | 0.02mL | EUR 140 |
PSMB8 Polyclonal Antibody |
|||
| MBS2528965-006mL | MyBiosource | 0.06mL | EUR 180 |
PSMB8 Polyclonal Antibody |
|||
| MBS2528965-012mL | MyBiosource | 0.12mL | EUR 260 |
PSMB8 Polyclonal Antibody |
|||
| MBS2528965-02mL | MyBiosource | 0.2mL | EUR 405 |
PSMB8 Polyclonal Antibody |
|||
| MBS2528965-5x02mL | MyBiosource | 5x0.2mL | EUR 1725 |
PSMB8 Conjugated Antibody |
|||
| MBS9451453-01mLAF350 | MyBiosource | 0.1mL(AF350) | EUR 480 |
PSMB8 Conjugated Antibody |
|||
| MBS9451453-01mLAF405 | MyBiosource | 0.1mL(AF405) | EUR 480 |
PSMB8 Conjugated Antibody |
|||
| MBS9451453-01mLAF488 | MyBiosource | 0.1mL(AF488) | EUR 480 |
PSMB8 Conjugated Antibody |
|||
| MBS9451453-01mLAF555 | MyBiosource | 0.1mL(AF555) | EUR 480 |
PSMB8 Conjugated Antibody |
|||
| MBS9451453-01mLBiotin | MyBiosource | 0.1mL(Biotin) | EUR 480 |
PSMB8 Polyclonal Antibody |
|||
| RD84433A-120uL | Reddot Biotech | 120μL | EUR 360 |
|
Description: The proteasome is a multicatalytic proteinase complex with a highly ordered ring-shaped 20S core structure. The core structure is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. This gene encodes a member of the proteasome B-type family, also known as the T1B family, that is a 20S core beta subunit. This gene is located in the class II region of the MHC (major histocompatibility complex). Expression of this gene is induced by gamma interferon and this gene product replaces catalytic subunit 3 (proteasome beta 5 subunit) in the immunoproteasome. Proteolytic processing is required to generate a mature subunit. Two alternative transcripts encoding two isoforms have been identified; both isoforms are processed to yield the same mature subunit. |
|||
PSMB8 Polyclonal Antibody |
|||
| RD84433A-200uL | Reddot Biotech | 200μL | EUR 630 |
|
Description: The proteasome is a multicatalytic proteinase complex with a highly ordered ring-shaped 20S core structure. The core structure is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. This gene encodes a member of the proteasome B-type family, also known as the T1B family, that is a 20S core beta subunit. This gene is located in the class II region of the MHC (major histocompatibility complex). Expression of this gene is induced by gamma interferon and this gene product replaces catalytic subunit 3 (proteasome beta 5 subunit) in the immunoproteasome. Proteolytic processing is required to generate a mature subunit. Two alternative transcripts encoding two isoforms have been identified; both isoforms are processed to yield the same mature subunit. |
|||
PSMB8 Polyclonal Antibody |
|||
| RD84433A-60uL | Reddot Biotech | 60μL | EUR 204 |
|
Description: The proteasome is a multicatalytic proteinase complex with a highly ordered ring-shaped 20S core structure. The core structure is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. This gene encodes a member of the proteasome B-type family, also known as the T1B family, that is a 20S core beta subunit. This gene is located in the class II region of the MHC (major histocompatibility complex). Expression of this gene is induced by gamma interferon and this gene product replaces catalytic subunit 3 (proteasome beta 5 subunit) in the immunoproteasome. Proteolytic processing is required to generate a mature subunit. Two alternative transcripts encoding two isoforms have been identified; both isoforms are processed to yield the same mature subunit. |
|||
PSMB8 Antibody (N-term) |
|||
| MBS9213569-008mL | MyBiosource | 0.08mL | EUR 210 |
PSMB8 Antibody (N-term) |
|||
| MBS9213569-04mL | MyBiosource | 0.4mL | EUR 430 |
PSMB8 Antibody (N-term) |
|||
| MBS9213569-5x04mL | MyBiosource | 5x0.4mL | EUR 1910 |
PSMB8 Antibody, HRP conjugated |
|||
| 1-CSB-PA018886LB01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA |
|||
PSMB8 Antibody, HRP Conjugated |
|||
| MBS7113267-005mL | MyBiosource | 0.05mL | EUR 190 |
PSMB8 Antibody, HRP Conjugated |
|||
| MBS7113267-01mL | MyBiosource | 0.1mL | EUR 270 |
PSMB8 Antibody, HRP Conjugated |
|||
| MBS7113267-5x01mL | MyBiosource | 5x0.1mL | EUR 1205 |
PSMB8 Antibody, FITC conjugated |
|||
| 1-CSB-PA018886LC01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA |
|||
OACD05288-1ML - PSMB8 Antibody |
|||
| OACD05288-1ML | Aviva Systems Biology | 1ml | EUR 649 |
OACD05289-1ML - PSMB8 Antibody |
|||
| OACD05289-1ML | Aviva Systems Biology | 1ml | EUR 659 |
OACD05290-1ML - PSMB8 Antibody |
|||
| OACD05290-1ML | Aviva Systems Biology | 1ml | EUR 639 |
PSMB8 Antibody, FITC Conjugated |
|||
| MBS7113268-005mL | MyBiosource | 0.05mL | EUR 190 |
PSMB8 Antibody, FITC Conjugated |
|||
| MBS7113268-01mL | MyBiosource | 0.1mL | EUR 270 |
PSMB8 Antibody, FITC Conjugated |
|||
| MBS7113268-5x01mL | MyBiosource | 5x0.1mL | EUR 1205 |
OAAN02231-50UL - PSMB8 Antibody |
|||
| OAAN02231-50UL | Aviva Systems Biology | 50ul | EUR 149 |
PSMB8 Antibody, Biotin conjugated |
|||
| 1-CSB-PA018886LD01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA |
|||
OACD05288-100UL - PSMB8 Antibody |
|||
| OACD05288-100UL | Aviva Systems Biology | 100ul | EUR 199 |
OACD05289-100UL - PSMB8 Antibody |
|||
| OACD05289-100UL | Aviva Systems Biology | 100ul | EUR 189 |
OACD05290-100UL - PSMB8 Antibody |
|||
| OACD05290-100UL | Aviva Systems Biology | 100ul | EUR 189 |
OAAN02231-100UL - PSMB8 Antibody |
|||
| OAAN02231-100UL | Aviva Systems Biology | 100ul | EUR 249 |
OAAN02231-200UL - PSMB8 Antibody |
|||
| OAAN02231-200UL | Aviva Systems Biology | 200ul | EUR 389 |
OAEB02189-100UG - PSMB8 Antibody |
|||
| OAEB02189-100UG | Aviva Systems Biology | 100ug | EUR 349 |
OAGA01026-100UL - PSMB8 antibody |
|||
| OAGA01026-100UL | Aviva Systems Biology | 100ul | EUR 369 |
PSMB8 Antibody, Biotin Conjugated |
|||
| MBS7113269-005mL | MyBiosource | 0.05mL | EUR 190 |
PSMB8 Antibody, Biotin Conjugated |
|||
| MBS7113269-01mL | MyBiosource | 0.1mL | EUR 270 |
PSMB8 Antibody, Biotin Conjugated |
|||
| MBS7113269-5x01mL | MyBiosource | 5x0.1mL | EUR 1205 |
Human, Rat, Mouse PSMB8 antibody |
|||
| P0987 | Omnimabs | 100ul | EUR 150 |